Pfizer Pflat In 2005: Revenue Will Be "Substantially Unchanged"
Pfizer expects flat revenue growth during 2005 in the face of patent expirations and the poor performance of its COX-2 inhibitors
Pfizer expects flat revenue growth during 2005 in the face of patent expirations and the poor performance of its COX-2 inhibitors